Stockscreener 앱 받기
18.45
0.32%
-0.0884
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
BCAX (Nasdaq) insider sale: 16,300 shares via option exercise (03/04/2026) - Stock Titan
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug - simplywall.st
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Bicara hire gets 115,000 stock options as job inducement - Stock Titan
BCAX (NASDAQ) insider to sell 13,555 shares after option exercise - Stock Titan
Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX) - Stock Titan
BCAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Bicara Therapeutics Inc benefit from rate cuts2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Major Insider Move Signals Growing Confidence in Bicara Therapeutics - TipRanks
Bicara Therapeutics (BCAX) stake reaches 11.5% at RA Capital group - Stock Titan
RA Capital funds boost Bicara Therapeutics (BCAX) stake with stock and warrants - Stock Titan
Assessing Bicara Therapeutics (BCAX) Valuation After Recent Share Price Moves And DCF Implied Upside - simplywall.st
Bicara Therapeutics (BCAX) President/COO sells 3,631 shares after option exercise - Stock Titan
Bicara Therapeutics closes $172.5 million stock offering By Investing.com - Investing.com India
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Bicara Therapeutics Strengthens Finances with Equity Offering - TipRanks
Bicara Therapeutics Inc. closes oversubscribed equity offering to fund ficerafusp alfa advancement - Traders Union
Bicara Therapeutics closes $172.5 million stock offering - Investing.com South Africa
Bicara Therapeutics (NASDAQ: BCAX) raises $161.8M to fund ficerafusp alfa - Stock Titan
Bicara raises $172.5M to back planned ficerafusp alfa U.S. launch - Stock Titan
Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX - Defense World
BCAX Should I Buy - Intellectia AI
Bicara Therapeutics prices $150 million stock offering at $16 By Investing.com - Investing.com Australia
Ryan Cohlhepp sells BCAX shares (BCAX) in multiple transactions - Stock Titan
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:BCAX) 2026-02-25 - Seeking Alpha
Bicara Therapeutics Announces Public Offering Details - Intellectia AI
Biotech prices $150M deal to fund solid tumor drug plans in US - Stock Titan
Bicara Therapeutics Prices $150 Million Securities Offering - marketscreener.com
Bicara Therapeutics (NASDAQ: BCAX) raises up to $172M via share and warrant sale - Stock Titan
Bicara Therapeutics Prices Public Offering at $16.00 per Share - Intellectia AI
Bicara Therapeutics prices $150 million stock offering at $16 - Investing.com
Bicara Therapeutics says co. prices public offering of 7,175,000 shares at $16.00 each - marketscreener.com
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Bicara Therapeutics Says Co. Prices Public Offering Of 7,175,000 Shares At $16.00 Each - TradingView
Bicara Therapeutics launches $150 million stock offering By Investing.com - Investing.com Australia
Bicara Therapeutics launches $150 million stock offering - Investing.com
Bicara Therapeutics announces proposed public offering of common stock - marketscreener.com
Bicara Therapeutics Announces Proposed Public Offering of Common Stock - TradingView
Cancer drug push: Bicara seeks $150M stock sale for launch prep - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap UpShould You Buy? - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Bicara Therapeutics stock rating reaffirmed by Citizens at Market Outperform - Investing.com UK
Bicara Therapeutics Shares New FICERA Data, Eyes Less Frequent Dosing in Head & Neck Cancer - MarketBeat
Biotech firm Bicara heads to Boston and Miami for investor talks - Stock Titan
Bicara Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Bicara Therapeutics Inc. (BCAX): Investor Outlook Reveals an 89.84% Potential Upside in Biotech Market - DirectorsTalk Interviews
BCAX: Ficerafusp alfa achieves deep, durable responses and strong safety in HPV-negative HNSCC at flexible dosing - TradingView
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen - Sahm
Bicara Therapeutics stock rating maintained at Market Outperform by Citizens - Investing.com India
BCAX: 2000mg ficerafusp alfa Q2W shows deep, durable responses in 1L HPV-negative HNSCC - TradingView
0.50%
자본화:
|
볼륨(24시간):